Bionano Genomics stock jumps 27% as efficiency and clinical adoption boost growth outlook

Bionano Genomics reported Q4 revenue of $8 million, slightly down 3% year-over-year but at the high end of guidance, while full-year gross margins surged to 46% from 1% in 2024 due to a focus on recurring revenue and cost cuts. The company cut operating expenses by 55%, ending the year with $29.6 million in liquidity, and is gaining traction as Optical Genome Mapping (OGM) adoption grows in clinical settings. Wall Street remains cautiously optimistic with price targets between $4 and $7+, expecting the leaner structure and increased reimbursement to support sustainable growth. The stock rose nearly 27% to $1.46 on Monday amid positive momentum and improving fundamentals.